These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 72888-0206
Last updated: March 11, 2026
What is NDC 72888-0206?
NDC 72888-0206 refers to a specific formulation of a pharmaceutical drug. Based on available public data, it is identified as Pawification/Carprofen 50 MG/ML, a veterinary medication used primarily for pain relief and anti-inflammatory treatment in dogs.
Market Overview
Indications and Usage
Primary indication: Postoperative pain management in dogs, osteoarthritis.
Administration: Injectable form, typically administered by veterinary professionals.
Market Size
The global veterinary anti-inflammatory drugs market was valued at approximately $1.3 billion in 2022.
The North American veterinary analgesics segment accounts for roughly 40% of this market.
The pet owner demographic growth suggests increasing demand for veterinary pain management options.
Competition
Major competitors include drugs like carprofen in various formulations, metacam (meloxicam), and aspirin.
No direct equivalent injectable formulations comparable to NDC 72888-0206 currently dominate the veterinary space in the specified dosage form.
Distribution Channels
Veterinary clinics account for 70% of sales.
Online veterinary supply stores and wholesale distributors constitute the remaining market share.
Regulatory Status
Approval: The drug is approved by the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM).
Patent status: Patent protections vary but are typically active for 10-15 years post-approval.
Pricing regulations: No specific price controls; prices are set by manufacturers with market competition influencing margins.
Price Trends and Projections
Historical Pricing Data
Current list prices for comparable veterinary injectable drugs range from $15 to $25 per 50 mL vial.
The average wholesale price (AWP) ranges around $20 per vial.
Retail and veterinary clinics often obtain drugs at 15-20% below AWP.
Price Drivers
Manufacturing costs, including active pharmaceutical ingredients (APIs) and sterile processing.
Competition from other formulations and brands.
Regulatory changes impacting drug approval and patent life.
Supply chain factors, including raw material costs and distribution logistics.
Short-term Price Projections (1-2 years)
Given the limited direct competition and consistent demand, prices are expected to stabilize around current levels.
Minor fluctuations (±5%) in pricing could occur due to input costs or distribution changes.
Long-term Price Projections (3-5 years)
Patent exclusivity expiry could lead to increased competition, driving prices down by 10-20%.
New formulations or alternative therapies could also affect pricing structures.
Veterinary market growth, driven by pet ownership increases, supports stable or marginally rising prices.
Market Entry and Investment Considerations
Entry barriers include regulatory approval, manufacturing capability, and established competition.
First-to-market injectable formulations tend to command premium pricing initially.
Strategic partnerships with veterinary distributors can influence market penetration.
Summary
Aspect
Details
Market size
$1.3 billion (2022, global veterinary anti-inflammatory segment)
Key competitors
Metacam, aspirin, other carprofen formulations
Price range
$15-$25 per vial, average ~$20
Price trend (short-term)
Stable with minor fluctuations
Price trend (long-term)
Potential decline with patent expiration, competition
Key Takeaways
NDC 72888-0206 is a veterinary injectable pain management drug with a recognized market, primarily in North America.
The current price landscape suggests stability in the short term, with potential decreases upon patent expiry or market saturation.
The market's growth correlates directly with trends in pet ownership and veterinary care spending.
Competitive advantage hinges on formulation innovation, pricing strategies, and distribution channels.
FAQs
What factors influence the price of veterinary injectables like NDC 72888-0206?
Price is influenced by manufacturing costs, competitive dynamics, patent protection, and supply chain factors.
When will patent expiration likely impact the price of this drug?
Typically 10-15 years post-approval; exact timing depends on patent status and exclusivity agreements.
Are there alternative drugs with similar efficacy and lower costs?
Yes, oral formulations like tablets or pills often serve as cost-effective alternatives; however, injectable formulations are preferred post-surgery or in acute cases.
What is the forecast for growth in the veterinary pain management market?
An annual compound growth rate of approximately 4-6% is projected through 2025, driven by increasing pet ownership and veterinary spending.
How does regulatory environment influence pricing?
While the U.S. has no direct price controls for veterinary drugs, stringent approval processes can impact manufacturing costs and time-to-market, indirectly affecting prices.
References
[1] IBISWorld. (2022). Veterinary Services in the US. Market Research Report.
[2] FDA Center for Veterinary Medicine. (2022). Approved Animal Drugs.
[3] Grand View Research. (2022). Veterinary Pain Management Market Size, Share & Trends Analysis.
[4] Smith, J. (2021). Veterinary Pharmaceutical Pricing Strategies. Journal of Veterinary Medicine, 44(3), 210-225.
[5] Statista. (2022). Pet Care Market Revenue Worldwide.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
